{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:43:45Z","timestamp":1776851025975,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Preference-based health-state utility values (HSUVs), such as the EuroQol five-dimensional questionnaire (EQ-5D-5L), are needed to calculate quality-adjusted life-years (QALYs) for cost-effectiveness analyses. However, these are rarely used in clinical trials of interventions in axial spondyloarthritis (axSpA). In these cases, mapping can be used to predict HSUVs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To develop mapping algorithms to estimate EQ-5D-5L HSUVs from the Bath Ankylosing Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) provided 5122 observations with complete BASDAI, BASFI, and EQ-5D-5L responses covering the full range of disease severity. We compared direct mapping using adjusted limited dependent variable mixture models (ALDVMMs) and optional inclusion of the gap between full health and the next feasible value with indirect response mapping using ordered probit (OPROBIT) and generalised ordered probit (GOPROBIT) models. Explanatory variables included BASDAI, BASFI, and age. Metrics to assess model goodness-of-fit and performance\/accuracy included Akaike and Bayesian information criteria (AIC\/BIC), mean absolute error (MAE) and root mean square error (RMSE), plotting predictive vs. observed estimates across the range of BASDAI\/BASFI and comparing simulated data with the original data set for the preferred\/best model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, the ALDVMM models that did not formally include the gap between full health and the next feasible value outperformed those that did. The four-component mixture models (with squared terms included) performed better than the three-component models. Response mapping using GOPROBIT (no squared terms included) or OPROBIT (with squared terms included) offered the next best performing models after the three-component ALDVMM (with squared terms). Simulated data of the preferred model (ALDVMM with four-components) did not significantly underestimate uncertainty across most of the range of EQ-5D-5L values, however the proportion of data at full health was underrepresented, likely due in part to model fitting on a small number of observations at this point in the actual data (4%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The mapping algorithms developed in this study enabled the generation of EQ-5D-5L utilities from BASDAI\/BASFI. The indirect mapping equations reported for the EQ-5D-5L facilitate the calculation of the EQ-5D-5L utility scores using other UK and country-specific value sets.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-022-01429-x","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T08:03:24Z","timestamp":1643875404000},"page":"1357-1369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3758-0566","authenticated-orcid":false,"given":"Aileen R.","family":"Neilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ejaz MI","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"McNamee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"1429_CR1","unstructured":"National Institute for Health and Care Excellence (NICE): Guide to the methods of technology appraisal 2013. Available at: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword. Accessed 26 Jan 2021"},{"key":"1429_CR2","unstructured":"Longworth, L., Rowen, D.: NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. London, NICE. 2011; [Cited 2014 Nov 13]; Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD-10-mapping-FINAL.pdf. Accessed 26 Jan 2021"},{"key":"1429_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","volume":"16","author":"L Longworth","year":"2013","unstructured":"Longworth, L., Rowen, D.: Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health 16, 202\u2013211 (2013)","journal-title":"Value Health"},{"issue":"1","key":"1429_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jval.2010.10.015","volume":"14","author":"JC Tosh","year":"2011","unstructured":"Tosh, J.C., Longworth, L.J., George, E.: Utility values in National institute for health and clinical excellence (NICE) technology appraisals. Value Health 14(1), 102\u2013109 (2011)","journal-title":"Value Health"},{"key":"1429_CR5","doi-asserted-by":"publisher","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2006","unstructured":"Sieper, J., Braun, J., Rudwaleit, M., Boonen, A., Zink, A.: Ankylosing spondylitis: an overview. Ann. Rheum. Dis. 61, iii8\u2013iii18 (2006)","journal-title":"Ann. Rheum. Dis."},{"key":"1429_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s10067-005-1150-5","volume":"25","author":"A \u00d6zg\u00fcl","year":"2006","unstructured":"\u00d6zg\u00fcl, A., Peker, F., Taskaynatan, M.A., Tan, A.K., Dincer, K., Kalyon, T.A.: Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin. Rheumatol. 25, 168\u2013174 (2006)","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"1429_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean, L.E., Jones, G.T., MacDonald, A.G., Downham, C., Sturrock, R.D., Macfarlane, G.J.: Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 53(4), 650\u2013657 (2014). https:\/\/doi.org\/10.1093\/rheumatology\/ket387","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1429_CR8","doi-asserted-by":"publisher","first-page":"i138","DOI":"10.1093\/rheumatology\/keu115.005","volume":"53","author":"MH Husain","year":"2014","unstructured":"Husain, M.H., Brophy Cooksey, R., et al.: The cost of ankylosing spondylitis to the UK NHS. Rheumatology 53(1), i138 (2014). https:\/\/doi.org\/10.1093\/rheumatology\/keu115.005","journal-title":"Rheumatology"},{"issue":"7","key":"1429_CR9","doi-asserted-by":"publisher","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","volume":"10","author":"R Cooksey","year":"2015","unstructured":"Cooksey, R., Husain, M.J., Brophy, S., Davies, H., Rahman, M.A., Atkinson, M.D., et al.: The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. PLoS ONE 10(7), e0126105 (2015). https:\/\/doi.org\/10.1371\/journal.pone.0126105","journal-title":"PLoS ONE"},{"issue":"7","key":"1429_CR10","doi-asserted-by":"publisher","first-page":"A541","DOI":"10.1016\/j.jval.2016.09.1130","volume":"19","author":"C Blanch","year":"2016","unstructured":"Blanch, C., Comellas, M., Prada, C., Lizan, L.: Economic burden of ankylosing spondylitis in Europe. A systematic review of the literature. Value Health 19(7), A541\u2013A542 (2016)","journal-title":"Value Health"},{"issue":"2","key":"1429_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3899\/jrheum.180477","volume":"46","author":"GJ Macfarlane","year":"2018","unstructured":"Macfarlane, G.J., Shim, J., Jones, G.T., Walker-Bone, K., Pathan, E.M., Dean, L.E.: Identifying persons with axial spondyloarthritis at risk of poor work outcome: results from the British society for rheumatology biologics register. J. Rheumatol. 46(2), 145\u2013152 (2018)","journal-title":"J. Rheumatol."},{"key":"1429_CR12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2001","unstructured":"Gorman, J.D., Sack, K.E., David, J.C.: Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor \u03b1. N. Engl. J. Med. 346, 1349\u20131356 (2001)","journal-title":"N. Engl. J. Med."},{"key":"1429_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.semarthrit.2012.06.002","volume":"42","author":"S Brophy","year":"2013","unstructured":"Brophy, S., Davies, H., Dennis, M.S., et al.: Fatigue in ankylosing spondylitis: treatment should focus on pain management. Sem. Arthritis Rheum. 42, 361\u2013367 (2013)","journal-title":"Sem. Arthritis Rheum."},{"issue":"11","key":"1429_CR14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1136\/annrheumdis-2018-213590","volume":"77","author":"J Shim","year":"2018","unstructured":"Shim, J., Jones, G.T., Pathan, E.M.I., Macfarlane, G.J.: Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British society for rheumatology biologics register (BSRBR-AS) and meta-analysis. Ann. Rheum. Dis. 77(11), 1578\u20131584 (2018)","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"1429_CR15","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1093\/rheumatology\/keaa132","volume":"59","author":"J Shim","year":"2020","unstructured":"Shim, J., Dean, L.E., Karabayas, M., Jones, G.T., Macfarlane, G.J., Basu, N.: Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. Rheumatology 59(11), 3408\u20133414 (2020)","journal-title":"Rheumatology"},{"issue":"2","key":"1429_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/annrheumdis-2019-216143","volume":"79","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane, G.J., Rotariu, O., Jones, G.T., Pathan, E., Dean, L.E.: Determining factors relating to poor quality of life in patients with axial spondylitis: results from the British society for rheumatology biologics register (BSRBR-AS). Ann. Rheum. Disease 79(2), 202\u2013208 (2020)","journal-title":"Ann. Rheum. Disease"},{"key":"1429_CR17","first-page":"2286","volume":"21","author":"S Garret","year":"1994","unstructured":"Garret, S., Jenkinson, T., Kennedy, L.G., Whitelock, H., Gaisfor, P., Calin, A.: A new approach to defining disease status in ankylosing spondylitis. The bath ankylosing spondylitis disease activity index. J. Rheumatol. 21, 2286\u20132291 (1994)","journal-title":"J. Rheumatol."},{"key":"1429_CR18","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin, A., Garrett, S., Whitelock, J., et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J. Rheumatol. 21, 2281\u20132285 (1994)","journal-title":"J. Rheumatol."},{"issue":"9","key":"1429_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett, M., et al.: Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol. Assess. 20(9), 1 (2016)","journal-title":"Health Technol. Assess."},{"key":"1429_CR20","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/rheumatology\/kem031","volume":"46","author":"MF Botteman","year":"2007","unstructured":"Botteman, M.F., Hay, J.W., Luo, M.P., et al.: The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology 46, 1320\u20131328 (2007)","journal-title":"Rheumatology"},{"issue":"8","key":"1429_CR21","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/rheumatology\/kem133","volume":"46","author":"RM Ara","year":"2007","unstructured":"Ara, R.M., Reynolds, A.V., Conway, P.: The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology 46(8), 1338\u20131344 (2007)","journal-title":"Rheumatology"},{"key":"1429_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1017\/S0266462307070432","volume":"23","author":"G Kobelt","year":"2007","unstructured":"Kobelt, G., Sobocki, P., Sieper, J., Branu, J.: Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int. J. Technol. Assess. Health Care 23, 368\u2013375 (2007)","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"11","key":"1429_CR23","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/keq222","volume":"49","author":"AR Neilson","year":"2010","unstructured":"Neilson, A.R., Sieper, J., Deeg, M.: Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology (Oxford) 49(11), 2122\u20132134 (2010)","journal-title":"Rheumatology (Oxford)"},{"key":"1429_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40273-013-0049-2","volume":"31","author":"N Armstrong","year":"2013","unstructured":"Armstrong, N., Joore, M., van Asselt, T., et al.: Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics 31, 415\u2013425 (2013)","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1429_CR25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jval.2017.09.017","volume":"21","author":"LA Gray","year":"2018","unstructured":"Gray, L.A., Hern\u00e1ndez Alava, M., Wailoo, A.J.: Development of methods for the mapping of utilities using mixture models: mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in patients with asthma. Value Health 21(6), 748\u2013757 (2018). https:\/\/doi.org\/10.1016\/j.jval.2017.09.017. (Epub 2017 Dec 14)","journal-title":"Value Health"},{"issue":"3","key":"1429_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40258-019-00467-6","volume":"17","author":"C Mukuria","year":"2019","unstructured":"Mukuria, C., Rowen, D., Harnam, S., Rawdin, A., Wong, R., Ara, R., Brazier, J.: An updated systematic review of studies mapping (or cross-walking) measures of health-related quality of life to generic preference-based measures to generated utility values. Appl. Health Econ. Health Policy 17(3), 295\u2013313 (2019). https:\/\/doi.org\/10.1007\/s40258-019-00467-6","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"4","key":"1429_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2015.02.016","volume":"18","author":"A Wailoo","year":"2015","unstructured":"Wailoo, A., Hernandez, M., Phillips, C., Brophy, S., Siebert, S.: Modelling health state utility values in ankylosing spondylitis. Value Health 18(4), 425\u2013431 (2015)","journal-title":"Value Health"},{"issue":"3","key":"1429_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jval.2011.12.014","volume":"15","author":"M Hern\u00e1ndez Alava","year":"2012","unstructured":"Hern\u00e1ndez Alava, M., Wailoo, A.J., Ara, R.: Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health 15(3), 550\u2013561 (2012)","journal-title":"Value Health"},{"key":"1429_CR29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/0272989X13500720","volume":"34","author":"M Hern\u00e1ndez Alava","year":"2013","unstructured":"Hern\u00e1ndez Alava, M., Wailoo, A.J., Ara, R.: A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med. Decis. Making 34, 919\u2013930 (2013)","journal-title":"Med. Decis. Making"},{"issue":"34","key":"1429_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24340","volume":"24","author":"M Hern\u00e1ndez Alava","year":"2020","unstructured":"Hern\u00e1ndez Alava, M., Wailoo, A., Pudney, S., Gray, L., Manca, A.: Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. Health Technol. Assess. 24(34), 1 (2020)","journal-title":"Health Technol. Assess."},{"issue":"5","key":"1429_CR31","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/rheumatology\/kes400","volume":"52","author":"M Hern\u00e1ndez Alava","year":"2013","unstructured":"Hern\u00e1ndez Alava, M., Wailoo, A., Wolfe, F., Michaud, K.: The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology 52(5), 944\u2013950 (2013)","journal-title":"Rheumatology"},{"key":"1429_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jhealeco.2017.06.013","volume":"55","author":"M Hern\u00e1ndez-Alava","year":"2017","unstructured":"Hern\u00e1ndez-Alava, M., Pudney, S.: Econometric modelling of multiple self-reports of health states: the switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis. J. Health Econ. 55, 139\u2013152 (2017). https:\/\/doi.org\/10.1016\/j.jhealeco.2017.06.013. (Epub 2017 Jul 4)","journal-title":"J. Health Econ."},{"issue":"1","key":"1429_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jval.2016.09.2398","volume":"20","author":"G Ward Fuller","year":"2017","unstructured":"Ward Fuller, G., Hernandez, M., Pallot, D., Lecky, F., Stevenson, M., Gabbe, B.: Health state preference weights for the glasgow outcome scale following traumatic brain injury: a systematic review and mapping study. Value Health 20(1), 141\u2013151 (2017). https:\/\/doi.org\/10.1016\/j.jval.2016.09.2398. (Epub 2016 Dec 28)","journal-title":"Value Health"},{"key":"1429_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12955-018-0857-3","volume":"16","author":"H Dakin","year":"2018","unstructured":"Dakin, H., Abel, L., Burns, R., Yang, Y.: Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual. Life Outcomes 16, 31 (2018). https:\/\/doi.org\/10.1186\/s12955-018-0857-3","journal-title":"Health Qual. Life Outcomes"},{"issue":"2","key":"1429_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14737167.2016.1200468","volume":"17","author":"T Mlcoch","year":"2017","unstructured":"Mlcoch, T., Sedova, L., Stolfa, J., et al.: Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Rev. Pharmacoecon. Outcomes Res. 17(2), 203\u2013211 (2017)","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"6","key":"1429_CR36","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s10198-020-01183-y","volume":"21","author":"AN Lamu","year":"2020","unstructured":"Lamu, A.N.: Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets. Eur. J. Health Econ. 21(6), 903\u2013915 (2020). https:\/\/doi.org\/10.1007\/s10198-020-01183-y. (Epub 2020 Apr 16. PMID: 32300999; PMCID: PMC7366565)","journal-title":"Eur. J. Health Econ."},{"issue":"6","key":"1429_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10198-017-0928-0","volume":"19","author":"BFM Wijnen","year":"2018","unstructured":"Wijnen, B.F.M., Mosweu, I., Majoie, M.H.J.M., Ridsdale, L., de Kinderen, R.J.A., Evers, S.M.A.A., McCrone, P.: A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. Eur. J. Health Econ. 19(6), 861\u2013870 (2018). https:\/\/doi.org\/10.1007\/s10198-017-0928-0. (Epub 2017 Sep 4. PMID: 28871490; PMCID: PMC6008365)","journal-title":"Eur. J. Health Econ."},{"issue":"11","key":"1429_CR38","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jval.2018.05.005","volume":"21","author":"A Moore","year":"2018","unstructured":"Moore, A., Young, C.A., Hughes, D.A.: Mapping ALSFRS-R and ALSUI to EQ-5D in patients with motor neuron disease. Value Health 21(11), 1322\u20131329 (2018). https:\/\/doi.org\/10.1016\/j.jval.2018.05.005. (Epub 2018 Jul 26 PMID: 30442280)","journal-title":"Value Health"},{"key":"1429_CR39","first-page":"347","volume":"16","author":"GJ Macfarlane","year":"2015","unstructured":"Macfarlane, G.J., Barnish, M.S., Jones, E.A., et al.: The British society for rheumatology biologics register in ankylosing spondylitis (BSRBR-AS) study: protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC 16, 347 (2015)","journal-title":"BMC"},{"key":"1429_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group: A new facility for the measurement of health-related quality of life. Health Policy 16, 199\u2013208 (1990)","journal-title":"Health Policy"},{"issue":"10","key":"1429_CR41","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20(10), 1727\u20131736 (2011)","journal-title":"Qual. Life Res."},{"issue":"1","key":"1429_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin, N.J., Shah, K.K., Feng, Y., Mulhern, B., van Hout, B.: Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 27(1), 7\u201322 (2018)","journal-title":"Health Econ."},{"key":"1429_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-017-0027-2","author":"J Round","year":"2017","unstructured":"Round, J., Hawton, A.: Statistical alchemy: conceptual validity and mapping to generate health state utility values. PharmacoEconomics Open (2017). https:\/\/doi.org\/10.1007\/s41669-017-0027-2","journal-title":"PharmacoEconomics Open"},{"key":"1429_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo, A.J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., Botteman, M., Busschbach, J.: Mapping to estimate health-state utility from non\u2013preference-based outcome measures: an ISPOR good practices for outcomes research taskforce report. Value Health 20, 18\u201327 (2017)","journal-title":"Value Health"},{"issue":"S1","key":"1429_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40273-017-0548-7","volume":"35","author":"R Ara","year":"2017","unstructured":"Ara, R., Rowen, D., Mukuria, C.: The use of mapping to estimate health state utility values. Pharmacoeconomics 35(S1), 57\u201366 (2017)","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1429_CR46","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","volume":"33","author":"S Petrou","year":"2015","unstructured":"Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., Gray, A.: The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. Pharmacoeconomics 33(10), 993\u20131011 (2015)","journal-title":"Pharmacoeconomics"},{"key":"1429_CR47","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez Alava. M., Wailoo. A: ALDVMM: a command for fitting adjusted limited dependent variable mixture models to EQ-5D. The Stata Journal 2015. https:\/\/www.sheffield.ac.uk\/polopoly_fs\/1.464135!\/file\/ALDVMM_forthcoming_Stata_Journal.pdf. Accessed 26 Jan 2021","DOI":"10.1177\/1536867X1501500307"},{"issue":"14","key":"1429_CR48","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12955-016-0455-1","volume":"12","author":"I Khan","year":"2016","unstructured":"Khan, I., Morris, S., Pashayan, N., Matata, B., Bashir, Z., Maguirre, J.: Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual. Life Outcomes 12(14), 60 (2016). https:\/\/doi.org\/10.1186\/s12955-016-0455-1","journal-title":"Health Qual. Life Outcomes"},{"key":"1429_CR49","unstructured":"National Institute for Health and Care Excellence (NICE). Position statement of the use of the EQ-5D-5L value set for England (updated October 2019). https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l. Accessed 26 Jan 2021"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-022-01429-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T17:08:03Z","timestamp":1665421683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-022-01429-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s10198-022-01429-x","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mixture models and response mapping can be used to crosswalk\u00a0between BASDAI\/BASFI and EQ-5D-5L to provide inputs for applied cost-effectiveness studies evaluating treatments in AxSpA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Precis"}}]}}